Tezepelumab

Summary

Tezepelumab (CHEMBL3707229) is an approved antibody (ATC R03DX11); indicated across 7 conditions including obstructive lung disease and asthma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: R03DX11
• Indications: 7 conditions
• Clinical trials: 49

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707229
Name	Tezepelumab
Type	Antibody
Max phase	4
ATC	R03DX11

Also known as: AMG 157, AMG-157, MEDI-19929, MEDI-9929, MEDI19929, MEDI9929, Tezepelumab, Tezepelumab ekko, Tezepelumab-ekko, Tezspire, TEZEPELUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
obstructive lung disease	4	MONDO:0002267	HP:0006536
asthma	4	MONDO:0004979	MONDO:0004979

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
eosinophilic esophagitis	3	MONDO:0005361	EFO:0004232
atopic eczema	2	MONDO:0004980	EFO:0000274
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
allergic disease	1	MONDO:0005271	MONDO:0005271

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 49.

Phase distribution

Phase	Trials
PHASE3	22
PHASE2	11
PHASE1	9
Not specified	5
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06705764	PHASE4	NOT_YET_RECRUITING	Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)
NCT05329194	PHASE4	COMPLETED	Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
NCT05583227	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05651841	PHASE3	RECRUITING	REVErsing Airway Remodelling With Tezepelumab
NCT06023589	PHASE3	RECRUITING	A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06473779	PHASE3	ACTIVE_NOT_RECRUITING	Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06706817	PHASE3	RECRUITING	A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
NCT06740045	PHASE3	NOT_YET_RECRUITING	Opening the Black Box on Tezepelumab’s Effect on Chronic Rhinosinusitis With Severe Asthma
NCT06878261	PHASE3	RECRUITING	A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06883305	PHASE3	RECRUITING	A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT07013123	PHASE3	NOT_YET_RECRUITING	Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
NCT07302516	PHASE3	NOT_YET_RECRUITING	Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma
NCT07363642	PHASE3	RECRUITING	Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
NCT07520162	PHASE3	RECRUITING	A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
NCT03347279	PHASE3	COMPLETED	Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
NCT03406078	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
NCT03706079	PHASE3	COMPLETED	Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
NCT03927157	PHASE3	COMPLETED	Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
NCT03968978	PHASE3	COMPLETED	Tezepelumab Home Use Study
NCT04851964	PHASE3	COMPLETED	Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
NCT05062759	PHASE3	COMPLETED	Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
NCT05274815	PHASE3	COMPLETED	Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
NCT05280418	PHASE3	COMPLETED	Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma
NCT05398263	PHASE3	TERMINATED	Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
NCT05507242	PHASE2	RECRUITING	Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD
NCT06189742	PHASE2	ACTIVE_NOT_RECRUITING	Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)
NCT06230354	PHASE2	ACTIVE_NOT_RECRUITING	Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
NCT07015996	PHASE2	NOT_YET_RECRUITING	Efficacy of Tezepelumab in Peanut Oral Immunotherapy
NCT02054130	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
NCT02525094	PHASE2	COMPLETED	Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
NCT02698501	PHASE2	COMPLETED	Effects of Anti-TSLP in Patients With Asthma
NCT03688074	PHASE2	COMPLETED	Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
NCT03809663	PHASE2	TERMINATED	A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
NCT04039113	PHASE2	COMPLETED	Tezepelumab COPD Exacerbation Study
NCT05740748	PHASE2	UNKNOWN	Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma
NCT07327697	PHASE1	NOT_YET_RECRUITING	A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects
NCT00757042	PHASE1	COMPLETED	Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis
NCT00972179	PHASE1	COMPLETED	Safety Study of Tezepelumab (AMG 157) in Healthy Adults
NCT01405963	PHASE1	COMPLETED	Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma
NCT01913028	PHASE1	COMPLETED	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects
NCT02512900	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
NCT03989544	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects
NCT04362410	PHASE1	COMPLETED	Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects
NCT04673630	PHASE1	COMPLETED	Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
NCT06438913	Not specified	NOT_YET_RECRUITING	Tezepelumab Treatment in Korean Severe Asthma Patients
NCT06948396	Not specified	ACTIVE_NOT_RECRUITING	Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
NCT06951867	Not specified	RECRUITING	Tezspire Cardiac Events PASS
NCT07046117	Not specified	NOT_YET_RECRUITING	Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps
NCT06455462	Not specified	COMPLETED	Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).